Earnings call transcript: Physitrack posts record Q3 2026 revenue as stock rises

Physitrack reported record Q3 2026 revenue of EUR 3.6 million, a 14% increase year-over-year, as the company's stock rose 2.48% to $12.4 in premarket trading. Investors focused on strong recurring revenue, early traction for new products, and improved margins as the company's main engine of growth, the Lifecare division, and the core home exercise prescription platform continued to expand.

The EMR product launch, which drew nearly 5,000 users across 500 clinics, was highlighted as a strategic step in integrating agentic AI, remote therapeutic monitoring, and educational modules into clinical workflows.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.